19 min listen
Episode 24: Taking Risks and Setting Precedent in Bioanalytical Assays for Cell & Gene Therapies
Episode 24: Taking Risks and Setting Precedent in Bioanalytical Assays for Cell & Gene Therapies
ratings:
Length:
28 minutes
Released:
Jan 22, 2021
Format:
Podcast episode
Description
There are no bad ideas in developing bioanalytical testing, says Jim McNally, CSO of BioAgilytix. Not all ideas will work, of course. But he has found that it is the outside-the-box ideas that often turn out to be the solution in challenging assay work. Dr. McNally speaks with The Chain about his background in bioanalytical testing and supporting clinical trials, the exciting future of cell and gene therapies, and the importance of setting precedent in bioanalysis of these new, life-saving therapies. It is an exciting time for gene therapy especially, and Dr. McNally shares how new immunogenicity data is getting us closer to bringing this therapy to more people.
Released:
Jan 22, 2021
Format:
Podcast episode
Titles in the series (63)
Episode 10: Intelligent Data Flow through Biotherapeutic Protein Development w/ Cenk Ündey, PhD by The Chain: Protein Engineering Podcast